German drug major Merck KgaA (MKGAY.PK) has announced positive results from two Phase II clinical trials of its investigational, targeted oncology molecule tepotinib in MET-positive, advanced hepatocellular carcinoma or HCC with Child-Pugh Class A liver function. The company noted that both studies met their primary endpoint.
from RTT - Biotech https://ift.tt/2LHSupA
via IFTTT
No comments:
Post a Comment